ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
8 001,80
-0,48%
Dow Jones
38 798,99
-0,22%
DAX
18 557,27
-0,48%
Brent Oil
79,395
0,00%
Bitcoin
69 406,75
0,11%
Registration Strip Icon for monitor Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. 2seventy bio Inc (TSVT)

  7. 2seventy bio Inc (TSVT) Actualités

TSVT

2seventy bio (TSVT)

2seventy bio Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:TSVT
DateHeureSourceTitreSymboleSociété
06/06/202401h16Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:TSVT2seventy bio Inc
23/05/202413h00Business Wire2seventy bio to Participate in Upcoming Investor ConferencesNASDAQ:TSVT2seventy bio Inc
09/05/202422h03Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:TSVT2seventy bio Inc
08/05/202413h09Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:TSVT2seventy bio Inc
08/05/202413h00Business Wire2seventy bio Reports First Quarter Financial Results and Recent Operational ProgressNASDAQ:TSVT2seventy bio Inc
03/05/202413h00Business Wire2seventy bio to Report First Quarter 2024 Financial Results on May 8, 2024NASDAQ:TSVT2seventy bio Inc
05/04/202415h05Business WireU.S. FDA Approves Bristol Myers Squibb and 2seventy bio’s Abecma for Triple-Class Exposed Relapsed or Refractory Multiple Myeloma After Two Prior Lines of TherapyNASDAQ:TSVT2seventy bio Inc
01/04/202413h30Business Wire2seventy bio Announces Completion of Oncology and Autoimmune Pipeline Divestiture to RegeneronNASDAQ:TSVT2seventy bio Inc
20/03/202422h04Business Wire2seventy bio Announces Appointments of Eli Casdin and Charles Newton to Board of DirectorsNASDAQ:TSVT2seventy bio Inc
15/03/202423h27Business WireFDA Advisory Committee Votes in Favor of Bristol Myers Squibb’s and 2seventy bio’s Abecma for Triple-Class Exposed Multiple Myeloma in Earlier Lines of TherapyNASDAQ:TSVT2seventy bio Inc
07/03/202422h02Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:TSVT2seventy bio Inc
05/03/202413h00Business Wire2seventy bio Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Operational ProgressNASDAQ:TSVT2seventy bio Inc
01/03/202413h00Business Wire2seventy bio to Report Fourth Quarter and Full Year 2023 Financial Results and Participate in Upcoming Investor ConferencesNASDAQ:TSVT2seventy bio Inc
05/02/202412h59Business WireBristol Myers Squibb and 2seventy bio Share Update on U.S. FDA Oncologic Drugs Advisory Committee Meeting for Abecma in Triple-Class Exposed Multiple Myeloma Based on KarMMa-3 StudyNASDAQ:TSVT2seventy bio Inc
02/02/202422h54Edgar (US Regulatory)Form 8-K/A - Current report: [Amend]NASDAQ:TSVT2seventy bio Inc
30/01/202415h25AllPennyStocks.comBiotech Shares Soar Premarket On Sale Of R&D AssetsNASDAQ:TSVT2seventy bio Inc
30/01/202413h01Business Wire2seventy bio Announces New Strategic Path ForwardNASDAQ:TSVT2seventy bio Inc
05/01/202422h31Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:TSVT2seventy bio Inc
12/12/202301h30Business WireAbecma Delivers Sustained Progression-Free Survival Versus Standard Regimens in Earlier Lines of Therapy for Relapsed and Refractory Multiple Myeloma Based on Longer-Term Follow-up from KarMMa-3NASDAQ:TSVT2seventy bio Inc
11/12/202313h00Business Wire2seventy bio to Host Investor Call at 8:00am ET on Tuesday, December 12 to Discuss Data from KarMMa-3 and KarMMa-2 Studies of Abecma (idecabtagene vicleucel)NASDAQ:TSVT2seventy bio Inc
06/12/202320h00Business Wire2seventy bio Reiterates Commitment to Maximizing Shareholder ValueNASDAQ:TSVT2seventy bio Inc
01/12/202312h49Edgar (US Regulatory)Form 10-Q/A - Quarterly report [Sections 13 or 15(d)]: [Amend]NASDAQ:TSVT2seventy bio Inc
01/12/202312h40Edgar (US Regulatory)Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend]NASDAQ:TSVT2seventy bio Inc
20/11/202320h31Dow Jones NewsTrending: Bristol Myers Squibb's Blood Cancer Treatment Approval Delayed by FDANASDAQ:TSVT2seventy bio Inc
20/11/202314h30Dow Jones News2seventy Bio Shares Fall Premarket on Abecma Expansion DelayNASDAQ:TSVT2seventy bio Inc
20/11/202313h56Dow Jones NewsFDA Advisory Panel to Meet on Earlier Use of Abecma From Bristol, 2seventyNASDAQ:TSVT2seventy bio Inc
20/11/202312h59Business WireBristol Myers Squibb and 2seventy bio Provide Update on U.S. FDA Review of sBLA for Abecma (idecabtagene vicleucel) in Earlier Lines of Therapy for Triple-Class Exposed Relapsed or Refractory Multiple MyelomaNASDAQ:TSVT2seventy bio Inc
14/11/202313h00Business Wire2seventy bio Reports Third Quarter Financial Results and Recent Operational ProgressNASDAQ:TSVT2seventy bio Inc
10/11/202313h00Business Wire2seventy bio to Report Third Quarter 2023 Financial Results on November 14, 2023NASDAQ:TSVT2seventy bio Inc
12/09/202313h00Business Wire2seventy bio Announces Strategic Restructuring to Prioritize Growth of Abecma, Streamline Pipeline Advancement and Preserve Financial RunwayNASDAQ:TSVT2seventy bio Inc
 Showing the most relevant articles for your search:NASDAQ:TSVT

Dernières Valeurs Consultées

LSE
93LJ
Westpac 24
ASX
AFV
NASDAQ
FJUGAX
S&P Dividend Aristocrats...
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés